270
Participants
Start Date
February 23, 2021
Primary Completion Date
February 15, 2026
Study Completion Date
February 15, 2026
Obinutuzumab
Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
Glofitamab
Participants will receive IV glofitamab for up to 12 cycles.
Rituxumab
Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.
Tocilizumab
Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).
Gemcitabine
Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
Oxaliplatin
Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
Chang Gung Medical Foundation - Linkou, Taoyuan District
Chang Gung Medical Foundation - Kaohsiung;Oncology, Kaoisung
Prince of Wales Hospital, Randwick
Rigshospitalet, København Ø
Peter Maccallum Cancer Centre, Melbourne
UZ Leuven Gasthuisberg, Leuven
Inselspital Bern, Insel-Gruppe AG, Bern
St Vincent's Hospital Melbourne, Fitzroy
Monash Health Monash Medical Centre, Clayton
CHU de Liège (Sart Tilman), Liège
Royal Adelaide Hospital, Adelaide
Sir Charles Gairdner Hospital, Nedlands
Universitätsspital Zürich, Zurich
Aarhus Universitetshospital Skejby, Aarhus N
Icahn School of Medicine at Mount Sinai, New York
National Cancer Center, Goyang-si
Seoul National University Bundang Hospital, Seongnam-si
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Duke University Medical Center, Durham
Hospital Universitario la Paz, Madrid
Baptist - MD Anderson Cancer Center, Jacksonville
Institut Bergonie, Bordeaux
Chu de Montpellier-St Eloi, Montpellier
CHU Pontchaillou, Rennes
Universitätsklinikum Gießen und Marburg GmbH Standort Gießen Medizinische Klinik I, Giessen
University of Mississippi Medical Center, Jackson
Taichung Veterans General Hospital, Xitun Dist.
Hospital Universitario Virgen del Rocio, Seville
Hospital Clinico Universitario de Valencia, Valencia
Pusan National University Hospital, Busan
Hopital Claude Huriez, Lille
Universitatsklinikum Frankfurt, Frankfurt
Centre Hospitalier Lyon Sud, Pierre-Bénite
Universitaetsklinikum Regensburg, Regensburg
Community Cancer Institute (CCI), Fresno
Hopital Henri Mondor, Créteil
Peking University Third Hospital, Beijing
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Tianjin Cancer Hospital, Tianjin
Zhejiang Cancer Hospital, Zhejiang
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Henan Cancer Hospital, Zhengzhou
Sun Yet-sen University Cancer Center, Guangzhou
University of Alabama at Birmingham, Birmingham
Massachusetts General Hospital, Boston
Rutgers Cancer Institute of New Jersey, New Brunswick
Uniwersyteckie Centrum Kliniczne, Gdansk
Centrum Onkologii Ziemi Lubelskiej im. ?w. Jana z Dukli, Lublin
Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn
Instytut Hematologii i Transfuzjologii, Warsaw
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroc?aw
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clínic i Provincial, Barcelona
Beatson West of Scotland Cancer Centre, Glasgow
St James's Institute of Oncology, Leeds
UCLH - Clinical Trials Pharmacy B&D Centre, London
Christie Hospital, Manchester
Nottingham City Hospital, Nottingham
Hoffmann-La Roche
INDUSTRY